

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)

Applicant/Patent Owner: ALLERGAN, INC.

Application No./Patent No.: 10/630,587 Filed/Issue Date: JULY 29, 2003

Entitled: METHOD FOR TREATING PAIN BY PERIPHERAL ADMINISTRATION OF A NEUROTOXIN

ALLERGAN, INC., a corporation
(Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. ☒ the assignee of the entire right, title, and interest; or
2. ☐ an assignee of less than the entire right, title and interest
(The extent (by percentage) of its ownership interest is _____ %)

in the patent application/patent identified above by virtue of either:

A. ☐ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

OR

B. ☒ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows:

1. From: K. Roger Aoki et al. To: Allergan Sales, Inc.
The document was recorded in the United States Patent and Trademark Office at
Reel 010729, Frame 0333, or for which a copy thereof is attached.
2. From: Allergan Sales, Inc. To: Allergan, Inc.
The document was recorded in the United States Patent and Trademark Office at
Reel 013897, Frame 0053, or for which a copy thereof is attached.
3. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.

☐ As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.

[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.



Signature

OCTOBER 2, 2006

Date

MATTHEW J. MALETTA

714-246-5185

Printed or Typed Name

Telephone Number

VP, Assistant General Counsel & Assist Secretary

Title

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



United States Patent and Trademark Office

[Home](#) | [Site Index](#) | [Search](#) | [Guides](#) | [Contacts](#) | [eBusiness](#) | [eBiz alerts](#) | [News](#) | [Help](#)[Assignments on the Web](#) > **Patent Query****Patent Assignment Abstract of Title**

NOTE: Results display only for issued patents and published applications. For pending or abandoned applications please consult USPTO staff.

Total Assignments: 2**Patent #:** 6464986 **Issue Dt:** 10/15/2002 **Application #:** 09550371 **Filing Dt:** 04/14/2000**Inventors:** Kei Roger Aoki, Minglei Cui, Stephen W. Jenkins**Title:** METHODS FOR TREATING PAIN BY ADMINISTRATION OF A BOTULINUM TOXIN**Assignment: 1****Reel/Frame:** 010729/0333**Recorded:** 04/14/2000**Pages:** 5**Conveyance:** ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).**Assignors:** AOKI, KEI ROGER**Exec Dt:** 04/13/2000

CUI, MINGLEI

Exec Dt: 04/13/2000

JENKINS, STEPHEN W.

Exec Dt: 04/13/2000**Assignee:** ALLERGAN SALES, INC.

2525 DUPONT DRIVE

IRVINE, CALIFORNIA 92612

Correspondent: ALLERGAN, INC. (T2-7H)

STEPHEN DONOVAN

2525 DUPONT DRIVE

IRVINE, CA 92612

Assignment: 2**Reel/Frame:** 013897/0053**Recorded:** 04/08/2003**Pages:** 17**Conveyance:** ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).**Assignor:** ALLERGAN SALES, INC. (MERGED INTO ALLERGAN SALES, LLC)**Exec Dt:** 04/01/2003**Assignee:** ALLERGAN, INC.

2525 DUPONT DRIVE

IRVINE, CALIFORNIA 92612

Correspondent: ALLERGAN, INC.

MARTIN A. VOET

2525 DUPONT DRIVE

IRVINE, CALIFORNIA 92612

Search Results as of: 10/02/2006 11:01 AM
If you have any comments or questions concerning the data displayed, contact PRD / Assignments at 571-272-3350.
Web interface last modified: July 26, 2006 v.1.10

[HOME](#) | [INDEX](#) | [SEARCH](#) | [eBUSINESS](#) | [CONTACT US](#) | [PRIVACY STATEMENT](#)

**RECORDATION FORM COVER SHEET
PATENTS ONLY**

To: The Commissioner of Patents and Trademarks,

Please record the attached original document(s) or copy(ies):

1. Submission Type:

☒ new☐ Correction of PTO error (Reel /frame)☐ Corrective Document (Reel /frame)

2. Conveyance Type:

☒ Assignment☐ License☐ Merger☐ Security Agreement☐ Change of Name☐ Other: _____

3.

CONVEYING PARTIES	
Names of Conveying Parties	Date of Conveyance
1. Kei Roger Aoki	04132000
2. Minglei Cui	04132000
3. Stephen W. Jenkins	04132000

☐ Additional Conveying Parties Attached

4.

RECEIVING PARTIES	
Names of Receiving Parties	
Name	Allergan Sales, Inc.
Address 1	2525 Dupont Drive
Address 2	Irvine, CA 92612

☐ Additional Receiving Parties Attached☐ If document is an assignment and the Receiving Party is not domiciled in the United States, an appointment of a Domestic Representative is attached.

5. **DOMESTIC REPRESENTATIVE NAME AND ADDRESS**

Name
Address 1
Address 2

8. **CORRESPONDENCE NAME AND ADDRESS**

Name	Stephen Donovan
Address 1	Allergan, Inc. (T2-7H)
Address 2	2525 Dupont Drive
Address 3	Irvine, CA 92612
Telephone and Fax	Tel: 714 246 4026; Fax: 714 246 4249

9. Total Number of pages of the conveying document, including attachments: 3

10. **APPLICATION NUMBER OR PATENT NUMBER (either; not both for same property)**

Application Number	Patent Number
Application Number	Patent Number
Application Number	Patent Number

11. If this document is being filed with a NEW patent application, enter the Docket No., Title of the Invention, and date of execution of the Assignment by the first inventor:

Title of Patent Application: METHOD FOR TREATING PAIN BY PERIPHERAL ADMINISTRATION OF A NEUROTOXIN
Docket No.: 17328(AP)
Date of Execution by First Inventor: 04132000

12. Total Number of Properties Involved: 1

13. The fee amount (37 CFR §3.41) of \$40.00

- ☒ may be debited from our Deposit Account No. 01-0885.
☐ is enclosed as check no. _____.

14. ☒ The Commissioner is authorized to deduct any additional fee amounts due in connection with the filing of this document from Deposit Account No. 01-0885.

To the best of my information and belief, all statements made herein are true, and any attached copy is a true copy of the original document.

Respectfully submitted,

SIGNATURE Stephen Donovan Date: 4/14/00

TYPED or PRINTED NAME STEPHEN DONOVAN REGISTRATION NO. 33,433

ASSIGNMENT

WHEREAS we, KEI ROGER AOKI, MINGLEI CUI and STEPHEN W. JENKINS, all of ORANGE COUNTY, CALIFORNIA (hereinafter referred to as ASSIGNOR), have invented and own a certain invention entitled: **METHOD FOR TREATING PAIN BY PERIPHERAL ADMINISTRATION OF A NEUROTOXIN**, for which application for Letters Patent of the United States has been executed on even date herewith.

WHEREAS: Allergan Sales, Inc., having its principal place of business at 2525 Dupont Drive, Irvine, CA 92612 (hereinafter referred to as ASSIGNEE), is desirous of acquiring the entire interest in, to and under said invention and in, to and under Letters Patent or similar legal protection to be obtained therefor in the United States and in any and all foreign countries.

NOW, THEREFORE, TO ALL WHOM IT MAY CONCERN: Be it known that in consideration of the payment by ASSIGNEE TO ASSIGNOR of the sum of One Dollar (\$1.00), the receipt of which is hereby acknowledged, and for other good and valuable consideration, ASSIGNOR hereby sells, assigns and transfers to ASSIGNEE the full and exclusive right, title and interest to said invention in the United States and its territorial possessions and in all foreign countries to all Letters Patent or similar legal protection in the United States and its territorial possessions and in any and all foreign countries to be obtained for said invention by said application or any continuation, divisional, renewal, substitute or reissue thereof or any legal equivalent thereof in a foreign country for the full term or terms for which the same may be granted.

ASSIGNOR hereby covenants that no assignment, sale, agreement or encumbrance has been or will be made or entered into which would conflict with this assignment and sale;

ASSIGNOR further covenants that ASSIGNEE will, upon its request, be provided promptly with all pertinent facts and documents relating to said application, said invention and said Letters Patent and legal equivalents in foreign countries as may be known and accessible to ASSIGNOR and will testify as to the same in any interference or litigation related thereto and will promptly execute and deliver to ASSIGNEE or its legal representative any and all papers, instruments or affidavits required to apply for, obtain, maintain, issue and enforce said application, said invention and said Letters Patent and said equivalent thereof in any foreign country which may be necessary or desirable to carry out the purposes thereof.

IN WITNESS WHEREOF, I/We have hereunto set hand and seal this


April 13, 2000.

Kei Roger Aoki
KEI ROGER AOKI

State of CALIFORNIA)
) ss:
County of ORANGE)

On APRIL 13 2000 before me, MARY LOU MC NOWN, Notary Public, personally appeared KEI ROGER AOKI, personally known to me (or proved to me on the basis of satisfactory evidence) to be the person whose name is subscribed to the within instrument and acknowledged to me that he/she executed the same in his/her authorized capacity, and that by his/her signature on the instrument the person, or the entity upon behalf of which the person acted, executed the instrument.

WITNESS my hand and official seal.



Mary Lou McNown
Notary Public

IN WITNESS WHEREOF, I/We have hereunto set hand and seal this


Apr. 13, 2000.

Minglei Cui
MINGLEI CUI

State of CALIFORNIA)
) ss:
County of ORANGE)

On APRIL 13 2000 before me, MARY LOU MC NOWN, Notary Public, personally appeared MINGLEI CUI, personally known to me (or proved to me on the basis of satisfactory evidence) to be the person whose name is subscribed to the within instrument and acknowledged to me that he/she executed the same in his/her authorized capacity, and that by his/her signature on the instrument the person, or the entity upon behalf of which the person acted, executed the instrument.


WITNESS my hand and official seal.



Mary Lou McNown
Notary Public

IN WITNESS WHEREOF, I/We have hereunto set hand and seal this


April 13, 2000.



STEPHEN W. JENKINS

State of CALIFORNIA)
) ss:
County of ORANGE)

On April 13, 2000 before me, Jennifer S. Lord, Notary Public, personally appeared STEPHEN W. JENKINS, personally known to me (or proved to me on the basis of satisfactory evidence) to be the person whose name is subscribed to the within instrument and acknowledged to me that ~~he~~/she executed the same in ~~his~~/her authorized capacity, and that by ~~his~~/her signature on the instrument the person, or the entity upon behalf of which the person acted, executed the instrument.

WITNESS my hand and official seal.


Notary Public





United States Patent and Trademark Office

[Home](#) | [Site Index](#) | [Search](#) | [Guides](#) | [Contacts](#) | [eBusiness](#) | [eBiz alerts](#) | [News](#) | [Help](#)


Assignments on the Web > Patent Query

Patent Assignment Details

NOTE: Results display only for issued patents and published applications. For pending or abandoned applications please consult USPTO staff.

Reel/Frame: 013897/0053

Pages: 17

Recorded: 04/08/2003

Conveyance: ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).

Total properties: 94

1	Patent #: 6294657	Issue Dt: 09/25/2001	Application #: 08996533	Filing Dt: 12/23/1997
	Title: RETINOID INDUCED GENE			
2	Patent #: 6440460	Issue Dt: 08/27/2002	Application #: 09117359	Filing Dt: 07/27/1998
	Title: PHARMACEUTICAL COMPOSITIONS CONTAINING BUFFERED ORTHO ESTER POLYMERS			
3	Patent #: 6277846	Issue Dt: 08/21/2001	Application #: 09138967	Filing Dt: 08/24/1998
	Title: USE OF PLATELET ACTIVATING FACTOR ANTAGONISTS AS ANTI-PRURITIC AGENTS			
4	Patent #: 6048873	Issue Dt: 04/11/2000	Application #: 09164949	Filing Dt: 10/01/1998
	Title: TETRAHIDROQUINOLIN-2-ONE 6 OR 7-YL, TETRAHIDROQUINILIN-2-THIONE 6 OR 7-YL PENTADIENOIC ACID AND RELATED DERIVATIVES HAVING RETINOID-LIKE BIOLOGICAL ACTIVITY			
5	Patent #: 6147224	Issue Dt: 11/14/2000	Application #: 09164950	Filing Dt: 10/01/1998
	Title: 2,4-PENTADIENOIC ACID DERIVATIVES HAVING SELECTIVE ACTIVITY FOR RETINOID X (RXR) RECEPTORS			
6	Patent #: 6258844	Issue Dt: 07/10/2001	Application #: 09194457	Filing Dt: 11/24/1998
	Title: CYCLOPENTANE(ENE)OIC ACID, 2-ALKENYL DERIVATIVES AS THERAPEUTIC AGENTS			
7	Patent #: 6194415	Issue Dt: 02/27/2001	Application #: 09225036	Filing Dt: 01/04/1999
	Title: METHOD OF USING (2-IMIDAZOLIN-2-YLAMINO) QUINOXALINES IN TREATING NEURAL INJURY			
8	Patent #: 6262117	Issue Dt: 07/17/2001	Application #: 09252318	Filing Dt: 02/18/1999
	Title: METHOD AND COMPOSITION FOR TREATING ACNE			
9	Patent #: 6248354	Issue Dt: 06/19/2001	Application #: 09262623	Filing Dt: 03/04/1999
	Title: CAPSULE SYSTEM			
10	Patent #: 6395878	Issue Dt: 05/28/2002	Application #: 09267423	Filing Dt: 03/12/1999
	Title: NUCLEIC ACID ENCODING A HUMAN EP PROSTAGLANDIN RECEPTOR			
11	Patent #: 6326389	Issue Dt: 12/04/2001	Application #: 09273832	Filing Dt: 03/22/1999
	Title: INHIBITION OF NONINACTIVATING NA CHANNELS OF MAMMALIAN OPTIC NERVE AS A MEANS OF PREVENTING OPTIC NERVE DEGENERATION ASSOCIATED WITH GLAUCOMA			
12	Patent #: 6350780	Issue Dt: 02/26/2002	Application #: 09286147	Filing Dt: 04/05/1999
	Title: METHODS AND COMPOSITIONS FOR DRUG DELIVERY			
13	Patent #: 6254860	Issue Dt: 07/03/2001	Application #: 09290833	Filing Dt: 04/13/1999
	Title: OCULAR TREATMENT USING CYCLOSPORIN-A DERIVATIVES			

14	Patent #: 6166244	Issue Dt: 12/26/2000	Application #: 09307061	Filing Dt: 05/07/1999
	Title: OXYGEN, SULFUR AND NITROGEN SUBSTITUTED CYCLOHEXENE AND CYCLOHEXANE DERIVATIVES HAVING RETINOID-LIKE BIOLOGICAL ACTIVITY			
15	Patent #: 6043381	Issue Dt: 03/28/2000	Application #: 09307062	Filing Dt: 05/07/1999
	Title: PROCESS FOR PREPARING SUBSTITUTED BENZO[1,2-G]-CHROM-3-ENE, BENZO[1,2-G]-THIOCHROM-3-ENE AND BENZO[1,2-G]-1,2-DIHYDROQUINOLINE DERIVATIVES			
16	Patent #: 6177588	Issue Dt: 01/23/2001	Application #: 09307073	Filing Dt: 05/07/1999
	Title: 1- ALKOXY AND 1-ACYLOXY SUBSTITUTED CYCLOHEX-1-ENE COMPOUNDS AND SULFUR AND 1-ALKOXYCARBONYL ANALOGS HAVING RETINOID-LIKE BIOLOGICAL ACTIVITY			
17	Patent #: 6166012	Issue Dt: 12/26/2000	Application #: 09365291	Filing Dt: 07/30/1999
	Title: ANTIBIOTIC COMPOSITIONS AND METHOD FOR USING SAME			
18	Patent #: 6093838	Issue Dt: 07/25/2000	Application #: 09375845	Filing Dt: 08/16/1999
	Title: AMINES SUBSTITUTED WITH A DIHYDRO-BENZOFURANYL OR WITH A DIHYDRO-ISOBENZOFURANYL GROUP, AN ARYL OR HETEROARYL GROUP AND AN ALKYL GROUP, HAVING RETINOID-LIKE BIOLOGICAL ACTIVITY			
19	Patent #: 6127382	Issue Dt: 10/03/2000	Application #: 09375846	Filing Dt: 08/16/1999
	Title: AMINES SUBSTITUTED WITH A TETRAHYDROQUINOLINYL GROUP AN ARYL OR HETEROARYL GROUP AND AN ALKYL GROUP, HAVING RETINOID-LIKE BIOLOGICAL ACTIVITY			
20	Patent #: 6358935	Issue Dt: 03/19/2002	Application #: 09388968	Filing Dt: 09/02/1999
	Title: PRESERVED CYCLODEXTRIN-CONTAINING COMPOSITIONS			
21	Patent #: 6113915	Issue Dt: 09/05/2000	Application #: 09417195	Filing Dt: 10/12/1999
	Title: METHODS FOR TREATING PAIN			
22	Patent #: 6265379	Issue Dt: 07/24/2001	Application #: 09418192	Filing Dt: 10/13/1999
	Title: METHOD FOR TREATING OTIC DISORDERS			
23	Patent #: 6294563	Issue Dt: 09/25/2001	Application #: 09440379	Filing Dt: 11/15/1999
	Title: COMBINATIONS OF PROSTAGLANDINS AND BRIMONIDINE OR DERIVATIVES THEREOF			
24	Patent #: 6380261	Issue Dt: 04/30/2002	Application #: 09445832	Filing Dt: 12/13/1999
	Title: CALCIUM BLOCKERS TO TREAT PROLIFERATIVE VITREORETINOPATHY			
25	Patent #: 6139845	Issue Dt: 10/31/2000	Application #: 09454842	Filing Dt: 12/07/1999
	Title: METHOD FOR TREATING CANCER WITH A NEUROTOXIN			
26	Patent #: 6313168	Issue Dt: 11/06/2001	Application #: 09464344	Filing Dt: 12/15/1999
	Title: USE OF RETINOID RECEPTOR ANTAGONISTS IN THE TREATMENT OF CARTILAGE AND BONE PATHOLOGIES			
27	Patent #: 6143306	Issue Dt: 11/07/2000	Application #: 09482831	Filing Dt: 01/11/2000
	Title: METHODS FOR TREATING PANCREATIC DISORDERS			
28	Patent #: 6337075	Issue Dt: 01/08/2002	Application #: 09491420	Filing Dt: 01/26/2000
	Title: Methods for treating diabetes			
29	Patent #: 6211385	Issue Dt: 04/03/2001	Application #: 09492492	Filing Dt: 01/27/2000
	Title: Process for preparing substituted benzo[1,2-G]-chrome-3-ene, benzo[1,2-G]-thiochrom-3-ene and benzo[1,2-G]-1,2-dihydroquinoline derivatives			
30	Patent #: 6395787	Issue Dt: 05/28/2002	Application #: 09500142	Filing Dt: 02/08/2000
	Title: Ocular hypotensive lipids			

31	Patent #: 6524580	Issue Dt: 02/25/2003	Application #: 09504538	Filing Dt: 02/15/2000
	Title: Method for treating thyroid disorders			
32	Patent #: 6358513	Issue Dt: 03/19/2002	Application #: 09512110	Filing Dt: 02/24/2000
	Title: Method for treating hashimoto's thyroiditis			
33	Patent #: 6450994	Issue Dt: 09/17/2002	Application #: 09526052	Filing Dt: 03/15/2000
	Title: STORAGE AND DELIVERY OF MULTI-DOSE, PRESERVATIVE-FREE PHARMACEUTICALS			
34	Patent #: 6403638	Issue Dt: 06/11/2002	Application #: 09532677	Filing Dt: 03/21/2000
	Title: 2,4-Pentadienoic acid derivatives having selective activity for retinoid x (rxr) receptors			
35	Patent #: 6303648	Issue Dt: 10/16/2001	Application #: 09548897	Filing Dt: 04/13/2000
	Title: Methods and compositions for the treatment and prevention of lung disease			
36	Patent #: 6492414	Issue Dt: 12/10/2002	Application #: 09549226	Filing Dt: 04/13/2000
	Title: METHODS AND COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF LUNG DISEASE			
37	Patent #: 6464986	Issue Dt: 10/15/2002	Application #: 09550371	Filing Dt: 04/14/2000
	Title: METHODS FOR TREATING PAIN BY ADMINISTRATION OF A BOTULINUM TOXIN			
38	Patent #: 6235289	Issue Dt: 05/22/2001	Application #: 09578097	Filing Dt: 05/25/2000
	Title: Intraspinal methods for treating pain			
39	Patent #: 6333037	Issue Dt: 12/25/2001	Application #: 09578181	Filing Dt: 05/25/2000
	Title: Methods for treating pain with a modified neurotoxin			
40	Patent #: 6306426	Issue Dt: 10/23/2001	Application #: 09587485	Filing Dt: 06/05/2000
	Title: Implant device with a retinoid for improved biocompatibility			
41	Patent #: 6452032	Issue Dt: 09/17/2002	Application #: 09591042	Filing Dt: 06/09/2000
	Title: ORGANOSILYL COMPOUNDS HAVING NUCLEAR HORMONE RECEPTOR MODULATING ACTIVITY			
42	Patent #: 6521641	Issue Dt: 02/18/2003	Application #: 09591253	Filing Dt: 06/09/2000
	Title: MALE ANTI-FERTILITY AGENTS			
43	Patent #: 6261572	Issue Dt: 07/17/2001	Application #: 09629748	Filing Dt: 07/31/2000
	Title: Method for treating a pancreatic disorder with a neurotoxin			
44	Patent #: 6350455	Issue Dt: 02/26/2002	Application #: 09631029	Filing Dt: 08/02/2000
	Title: Method for treating a catecholamine secretion			
45	Patent #: 6368605	Issue Dt: 04/09/2002	Application #: 09631030	Filing Dt: 08/02/2000
	Title: Method for treating cancer with a neurotoxin to improve patient function			
46	Patent #: 6465646	Issue Dt: 10/15/2002	Application #: 09634726	Filing Dt: 08/04/2000
	Title: 1-ALKOXY AND 1-ACYLOXY SUBSTITUTED CYCLOHEX-1-ENE COMPOUNDS AND SULFUR AND 1-ALKOXYCARBONYL ANALOGS HAVING RETINOID-LIKE BIOLOGICAL ACTIVITY			
47	Patent #: 6465647	Issue Dt: 10/15/2002	Application #: 09634727	Filing Dt: 08/04/2000
	Title: OXYGEN, SULFUR AND NITROGEN SUBSTITUTED CYCLOHEXENE AND CYCLOHEXANE DERIVATIVES HAVING RETINOID-LIKE BIOLOGICAL ACTIVITY			
48	Patent #: 6291677	Issue Dt: 09/18/2001	Application #: 09651001	Filing Dt: 08/29/2000
	Title: Compounds having activity as inhibitors of cytochrome P450RAI			
49	Patent #: 6303785	Issue Dt: 10/16/2001	Application #: 09651003	Filing Dt: 08/29/2000
	Title: Compounds having activity as inhibitors of cytochrome P450RAI			

50	Patent #: 6369261	Issue Dt: 04/09/2002	Application #: 09651004	Filing Dt: 08/29/2000
	Title: Compounds having activity as inhibitors of cytochrome P450RAI			
51	Patent #: 6387951	Issue Dt: 05/14/2002	Application #: 09651234	Filing Dt: 08/29/2000
	Title: COMPOUNDS HAVING ACTIVITY AS INHIBITORS OF CYTOCHROME P450RAI			
52	Patent #: 6380256	Issue Dt: 04/30/2002	Application #: 09651564	Filing Dt: 08/29/2000
	Title: COMPOUNDS HAVING ACTIVITY AS INHIBITORS OF CYTOCHROME P450RAI			
53	Patent #: 6369225	Issue Dt: 04/09/2002	Application #: 09651566	Filing Dt: 08/29/2000
	Title: Compounds having activity as inhibitors of Cytochrome P450RAI			
54	Patent #: 6248741	Issue Dt: 06/19/2001	Application #: 09655579	Filing Dt: 09/06/2000
	Title: Method of using (2-imidazolin-2-ylamino) quinoxalines in treating ocular neural injury			
55	Patent #: 6248783	Issue Dt: 06/19/2001	Application #: 09665791	Filing Dt: 09/20/2000
	Title: Cyclopentane 1-hydroxy alkyl or alkenyl-2-one or 2-hydroxy derivatives as therapeutic agents			
56	Patent #: 6291522	Issue Dt: 09/18/2001	Application #: 09671492	Filing Dt: 09/27/2000
	Title: Cyclopentane heptan(ENE)oic acid, 2-thiocarbamoyloxy and 2-carbamoyloxy compounds as therapeutic agents			
57	Patent #: 6313107	Issue Dt: 11/06/2001	Application #: 09672751	Filing Dt: 09/28/2000
	Title: Methods of providing and using compounds having activity as inhibitors of cytochrome P450RAI			
58	Patent #: 6423319	Issue Dt: 07/23/2002	Application #: 09678189	Filing Dt: 10/04/2000
	Title: METHODS FOR TREATING MUSCLE INJURIES			
59	Patent #: 6329369	Issue Dt: 12/11/2001	Application #: 09679919	Filing Dt: 10/05/2000
	Title: Compounds and method of treatment having agonist-like activity selective at alpha 2B or 2B/2C adrenergic receptors			
60	Patent #: 6492361	Issue Dt: 12/10/2002	Application #: 09680810	Filing Dt: 10/05/2000
	Title: ANTIBIOTIC COMPOSITIONS AND METHODS FOR USING SAME			
61	Patent #: 6376533	Issue Dt: 04/23/2002	Application #: 09693722	Filing Dt: 10/20/2000
	Title: Omega-cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists			
62	Patent #: 6328977	Issue Dt: 12/11/2001	Application #: 09704440	Filing Dt: 11/01/2000
	Title: Method for treating hyperparathyroidism			
63	Patent #: 6319506	Issue Dt: 11/20/2001	Application #: 09704441	Filing Dt: 11/01/2000
	Title: Method for treating hypercalcemia			
64	Patent #: 6447785	Issue Dt: 09/10/2002	Application #: 09706174	Filing Dt: 11/02/2000
	Title: METHOD FOR TREATING HYPERCALCEMIA			
65	Patent #: 6533764	Issue Dt: 03/18/2003	Application #: 09707006	Filing Dt: 11/06/2000
	Title: TWIST HOUSING APPARATUS FOR INSTILLING A MEDICATION INTO AN EYE			
66	Patent #: 6534542	Issue Dt: 03/18/2003	Application #: 09794874	Filing Dt: 02/27/2001
	Publication #: US20020161051	Pub Dt: 10/31/2002		
	Title: (2-HYDROXY)ETHYL-THIOUREAS USEFUL AS MODULATORS OF ALPHA2B ADRENERGIC RECEPTORS			
67	Patent #: 6372226	Issue Dt: 04/16/2002	Application #: 09797556	Filing Dt: 03/01/2001
	Publication #: US20010012828	Pub Dt: 08/09/2001		
	Title: Intraspinal botulinum toxin for treating pain			

- 68** **Patent #:** 6387950 **Issue Dt:** 05/14/2002 **Application #:** 09824111 **Filing Dt:** 04/02/2001
Publication #: US20010039293 **Pub Dt:** 11/08/2001
Title: TREATMENT OF TUMORS WITH RARALPHA SELECTIVE RETINOID COMPOUNDS IN COMBINATION WITH OTHER ANTI-TUMOR AGENTS
- 69** **Patent #:** 6399774 **Issue Dt:** 06/04/2002 **Application #:** 09829097 **Filing Dt:** 04/09/2001
Title: COMPOUNDS HAVING ACTIVITY AS INHIBITORS OF CYTOCHROME P450RAI
- 70** **Patent #:** 6359135 **Issue Dt:** 03/19/2002 **Application #:** 09829098 **Filing Dt:** 04/09/2001
Title: Compounds having activity as inhibitors of cytochrome P450RAI
- 71** **Patent #:** 6521613 **Issue Dt:** 02/18/2003 **Application #:** 09829641 **Filing Dt:** 04/10/2001
Publication #: US20020193449 **Pub Dt:** 12/19/2002
Title: LACTAM COMPOUNDS FOR PENETRATION ENHANCEMENT
- 72** **Patent #:** 6369089 **Issue Dt:** 04/09/2002 **Application #:** 09840675 **Filing Dt:** 04/23/2001
Title: Interheteroaryl 7-Oxabicyclic [2.2.1]heptane oxazoles as prostaglandin F2alpha antagonists
- 73** **Patent #:** 6410544 **Issue Dt:** 06/25/2002 **Application #:** 09842299 **Filing Dt:** 04/25/2001
Title: CHOLINERGIC AGENTS IN THE TREATMENT OF PRESBYOPIA
- 74** **Patent #:** 6307092 **Issue Dt:** 10/23/2001 **Application #:** 09850834 **Filing Dt:** 05/08/2001
Title: Cyclopentane, 1-hydroxy alkyl or alkenyl-2-one or 2-hydroxy derivatives as therapeutic agents
- 75** **Patent #:** 6410591 **Issue Dt:** 06/25/2002 **Application #:** 09851296 **Filing Dt:** 05/08/2001
Title: 3,7 OR 3 AND 7 THIA OR OXA PROSTANOIC ACID DERIVATIVES AS AGENTS FOR LOWERING INTRAOCULAR PRESSURE
- 76** **Patent #:** 6531504 **Issue Dt:** 03/11/2003 **Application #:** 09859770 **Filing Dt:** 05/17/2001
Publication #: US20020177620 **Pub Dt:** 11/28/2002
Title: PROSTANOIC ACID DERIVATIVES AS AGENTS FOR LOWERING INTRAOCULAR PRESSURE
- 77** **Patent #:** 6358926 **Issue Dt:** 03/19/2002 **Application #:** 09864447 **Filing Dt:** 05/24/2001
Publication #: US20010025024 **Pub Dt:** 09/27/2001
Title: NEUROTOXIN THERAPY FOR INNER EAR DISORDERS
- 78** **Patent #:** 6350442 **Issue Dt:** 02/26/2002 **Application #:** 09870256 **Filing Dt:** 05/30/2001
Publication #: US20010036449 **Pub Dt:** 11/01/2001
Title: Ocular treatment using cyclosporin-A derivatives
- 79** **Patent #:** 6387892 **Issue Dt:** 05/14/2002 **Application #:** 09875967 **Filing Dt:** 06/07/2001
Title: METHODS OF PROVIDING AND USING COMPOUNDS HAVING ACTIVITY AS INHIBITORS OF CYTOCHROME P450RAI
- 80** **Patent #:** 6380250 **Issue Dt:** 04/30/2002 **Application #:** 09876808 **Filing Dt:** 06/06/2001
Publication #: US20020058692 **Pub Dt:** 05/16/2002
Title: CYCLOPENTANE HEPTAN(ENE)OIC ACID, 2-THIOCARBAMOYLOXY AND 2-CARBAMOYLOXY COMPOUNDS AS THERAPEUTIC AGENTS
- 81** **Patent #:** 6476064 **Issue Dt:** 11/05/2002 **Application #:** 09880272 **Filing Dt:** 06/13/2001
Title: CYCLOPENTANE HEPTAN(ENE) ACYL SULFONAMIDE, 2-ALKYL OR 2-ARYLALKYL, OR 2-HETEROARYLALKENYL DERIVATIVES AS THERAPEUTIC AGENTS
- 82** **Patent #:** 6380251 **Issue Dt:** 04/30/2002 **Application #:** 09903971 **Filing Dt:** 08/10/2001
Title: CYCLOPENTANE HEPTAN(ENE)OIC ACID, 2-THIOCARBAMOYLOXY AND 2-CARBAMOYLOXY COMPOUNDS AS THERAPEUTIC AGENTS

- 83 Patent #:** [6359181](#) **Issue Dt:** 03/19/2002 **Application #:** 09915908 **Filing Dt:** 07/26/2001
Title: Cyclopentane 1-hydroxy alkyl or alkenyl-2-one or 2-hydroxy derivatives as therapeutic agents
- 84 Patent #:** [6500436](#) **Issue Dt:** 12/31/2002 **Application #:** 09922093 **Filing Dt:** 08/03/2001
Publication #: [US20020037833](#) **Pub Dt:** 03/28/2002
Title: CLOSTRIDIAL TOXIN DERIVATIVES AND METHODS FOR TREATING PAIN
- 85 Patent #:** [6455062](#) **Issue Dt:** 09/24/2002 **Application #:** 09935360 **Filing Dt:** 08/21/2001
Title: IMPLANT DEVICE WITH A RETINOID FOR IMPROVED BIOCOMPATIBILITY
- 86 Patent #:** [6420402](#) **Issue Dt:** 07/16/2002 **Application #:** 09935554 **Filing Dt:** 08/21/2001
Publication #: [US20020013353](#) **Pub Dt:** 01/31/2002
Title: INHIBITION OF NONINACTIVATING NA CHANNELS OF MAMMALIAN OPTIC NERVE AS A MEANS OF PREVENTING OPTIC NERVE DEGENERATION ASSOCIATED WITH GLAUCOMA
- 87 Patent #:** [6426358](#) **Issue Dt:** 07/30/2002 **Application #:** 09952733 **Filing Dt:** 09/14/2001
Publication #: [US20020040042](#) **Pub Dt:** 04/04/2002
Title: INHIBITION OF NONINACTIVATING NA CHANNELS OF MAMMALIAN OPTIC NERVE AS A MEANS OF PREVENTING OPTIC NERVE DEGENERATION ASSOCIATED WITH GLAUCOMA
- 88 Patent #:** [6495552](#) **Issue Dt:** 12/17/2002 **Application #:** 09963318 **Filing Dt:** 06/07/2001
Publication #: [US20020132796](#) **Pub Dt:** 09/19/2002
Title: METHODS OF PROVIDING AND USING COMPOUNDS HAVING ACTIVITY AS INHIBITORS OF CYTOCHROME P450RAI
- 89 Patent #:** [6388105](#) **Issue Dt:** 05/14/2002 **Application #:** 09967130 **Filing Dt:** 09/27/2001
Title: BENZOFURAN, INDOLE OR BENZOTHIOPHENE 2,4-PENTADIENOIC ACID DERIVATIVES HAVING SELECTIVE ACTIVITY FOR RETINOID X (RXR) RECEPTORS
- 90 Patent #:** [6416765](#) **Issue Dt:** 07/09/2002 **Application #:** 09972702 **Filing Dt:** 10/03/2001
Publication #: [US20020031529](#) **Pub Dt:** 03/14/2002
Title: NEUROTOXIN THERAPY FOR DIABETES
- 91 Patent #:** [6537568](#) **Issue Dt:** 03/25/2003 **Application #:** 09982219 **Filing Dt:** 10/17/2001
Publication #: [US20020022047](#) **Pub Dt:** 02/21/2002
Title: IMPLANT DEVICE WITH A RETINOID FOR IMPROVED BIOCOMPATIBILITY
- 92 Patent #:** [6531599](#) **Issue Dt:** 03/11/2003 **Application #:** 10004914 **Filing Dt:** 12/05/2001
Publication #: [US20020193578](#) **Pub Dt:** 12/19/2002
Title: COMPOUNDS HAVING ACTIVITY AS INHIBITORS OF CYTOCHROME P450RAI
- 93 Patent #:** [6479458](#) **Issue Dt:** 11/12/2002 **Application #:** 10005829 **Filing Dt:** 11/08/2001
Title: TARGETING THE REVERSE MODE OF THE NA⁺/CA²⁺ EXCHANGER FOR THE TREATMENT OF OPTIC NEUROPATHY ASSOCIATED WITH GLAUCOMA AND ISCHEMIC OPTIC NEUROPATHY
- 94 Patent #:** [6511999](#) **Issue Dt:** 01/28/2003 **Application #:** 10071449 **Filing Dt:** 02/08/2002
Publication #: [US20020128233](#) **Pub Dt:** 09/12/2002
Title: INTERHETEROARYL 7-OXABICYCLIC [2.2.1]HEPTANE OXAZOLES AS PROSTAGLANDIN F2ALPHA ANTAGONISTS

Assignor

1 [ALLERGAN SALES, INC. \(MERGED INTO ALLERGAN SALES, LLC\)](#)

Exec Dt: 04/01/2003

Assignee

1 [ALLERGAN, INC.](#)

2525 DUPONT DRIVE

IRVINE, CALIFORNIA 92612

Correspondence name and address

ALLERGAN, INC.
MARTIN A. VOET
2525 DUPONT DRIVE
IRVINE, CALIFORNIA 92612

Search Results as of: 10/02/2006 11:00 AM
If you have any comments or questions concerning the data displayed, contact PRD / Assignments at 571-272-3350.
Web interface last modified: July 26, 2006 v.1.10

| [HOME](#) | [INDEX](#) | [SEARCH](#) | [eBUSINESS](#) | [CONTACT US](#) | [PRIVACY STATEMENT](#)

54

Rec'd in USPTO/PCT Office. Date Stamp and Return Card.

Date: April 2, 2003

Serial No.: 113 - See attached
Appendix (3 pages)

Title: 113

Dkt. No.: 113

Enclosed Are:

☐ Specification # _____, Claims # _____,

and Abstract # _____

☐ Drawings (_____ sheets)

_____ Formal _____ Informal

☐ Info. Disc. Statement

☐ Priority Documents # _____

☐ PTO 1449 W/References

☐ PCT Request (# pgs. _____)

☐ PCT Demand (# pgs. _____)

☐ PCT Response (# pgs. _____)

☐ PCT Amendment (# pgs. _____)

☐ Declaration, Power of Attorney

☒ Assignment & Cover Sheet
(covering 113 applications)

☐ Amendment (Final) (# pgs. _____)

☐ Certificate of Mailing

☐ Issue Fee Transmittal

☐ Transmittal Letter

☐ Extension of Time

☐ Express Mail No. _____

(Assignment for pending

Allergan Sales, Inc. applica-
tions to ALLERGAN, INC.)

~~Certif. Under 37 CFR 1.10~~

RECORDATION FORM COVER SHEET PATENTS ONLY

To: The Commissioner of Patents and Trademarks,

Please record the attached original document(s) or copy(ies):

1. Submission Type:

☒ new

☐ Correction of PTO error (Reel /frame)

☐ Corrective Document (Reel /frame)

2. Conveyance Type:

☒ Assignment

☐ License

☐ Merger

☐ Security Agreement

☐ Change of Name

☐ Other: _____

3.

CONVEYING PARTIES	
Names of Conveying Parties	Date of Conveyance
1. Allergan Sales, Inc. (merged into Allergan Sales, LLC 6/3/2002)	March 31, 2003
2.	
3.	

☐ Additional Conveying Parties Attached

4.

RECEIVING PARTIES
Names of Receiving Parties
Name Allergan, Inc.
Address 1 2525 Dupont Drive
Address 2 Irvine, CA 92612

☐ Additional Receiving Parties Attached

☐ If document is an assignment and the Receiving Party is not domiciled in the United States, an appointment of a Domestic Representative is attached.

5.

DOMESTIC REPRESENTATIVE NAME AND ADDRESS
Name
Address 1
Address 2

6.

CORRESPONDENCE NAME AND ADDRESS
Name Martin A. Voet (T2-7H)
Address 1 Allergan, Inc.
Address 2 2525 Dupont Drive, Irvine, CA 92612
Telephone 714-246-5894 and Fax 714-246-4249

7. Total Number of pages of the conveying document, including attachments: 17 pages

8.

APPLICATION NUMBER OR PATENT NUMBER (either; not both for same property)	
Application Number see attached Appendix A (3 pages)	Patent Number
Application Number	Patent Number

9. If this document is being filed with a NEW patent application, enter the Docket No., Title of the Invention, and date of execution of the Assignment by the first inventor:

Title of Patent Application: _____
 Docket No.: _____
 Date of Execution by First Inventor: _____

10. Total Number of Properties Involved: 11111. The fee amount (37 CFR §3.41) of \$ 4,440

☒ may be debited from our Deposit Account No. 01-0885.
☐ is enclosed as check no. _____

12. ☒ The Commissioner is authorized to deduct any additional fee amounts due in connection with the filing of this document from Deposit Account No. 01-0885.

To the best of my information and belief, all statements made herein are true, and any attached copy is a true copy of the original document.

Respectfully submitted,

SIGNATURE

Date: 7/2/2003TYPED or PRINTED NAME: Martin A. Voet. REGISTRATION NO. 25,208

CERTIFICATE OF MAILING

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE WITH SUFFICIENT POSTAGE AS FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED TO: BOX ASSIGNMENT, COMMISSIONER FOR PATENTS, WASHINGTON, D.C. 20231 ON April 2, 2003 (Date)

Name of person making deposit: Mary Lou McNown

Signature: _____ Date: _____

ASSIGNMENT

WHEREAS: ALLERGAN, INC., a Delaware corporation, having its principal place of business at 2525 Dupont Drive, Irvine, California 92612 (hereinafter referred to as ASSIGNEE), is desirous of acquiring the entire right, title and interest in, to and under certain inventions and in, to and under corresponding Letters Patent or similar legal protection to be obtained therefor in the United States and in any and all foreign countries.

WHEREAS: On June 3, 2002, ALLERGAN SALES, INC., a California corporation, was merged into ALLERGAN SALES, LLC, a Delaware limited liability company pursuant to the "Agreement and Plan of Merger" filed with the Secretary of State of the State of California and with the Secretary of State of the State of Delaware (copy attached).

WHEREAS: ALLERGAN SALES, LLC, having its principal place of business at 2525 Dupont Drive, Irvine, California 92612 (hereinafter ASSIGNOR) by virtue of the above-mentioned merger owns the entire right, title and interest in, to and under certain inventions, corresponding U.S. patent applications and foreign rights directed thereto.

NOW, THEREFORE, TO ALL WHOM IT MAY CONCERN: Be it known that in consideration of the payment by ASSIGNEE TO ASSIGNOR of the sum of One Dollar (\$1.00), the receipt of which is hereby acknowledged, and for other good and valuable consideration, ASSIGNOR hereby sells, assigns and transfers to ASSIGNEE the entire right, title and interest in, to and under certain inventions in the United States and its territorial possessions and in all foreign countries to all Letters Patents or similar legal protection in the United States and its territorial possessions and in any and all foreign countries to be obtained for certain inventions by certain applications set forth in Appendix "A" and any continuation, divisional, renewal, substitute or reissue thereof for the full term or

terms for which the same may be granted; said sale,
transfer and assignment effective June 3, 2002.

IN WITNESS WHEREOF, I/We have hereunto set hand and seal
this 31 day of March 2003.

ALLERGAN SALES, LLC

By: Martin A. Voet
Martin A. Voet
Assistant Secretary

State of CALIFORNIA)
(ss.
County of ORANGE)

On March 31, 2003, before me, Mary Lou McNown,
notary public, personally appeared MARTIN A. VOET
personally known to me to be the person whose name is
subscribed to the within instrument and acknowledged to me
that he executed the same in his authorized capacity, and
that by his signature on the instrument the person, or the
entity upon behalf of which the person acted, executed the
instrument.

WITNESS my hand and official seal.

Mary Lou McNown
Signature of Notary Public

APPENDIX "A" (Page 1)

<u>SERIAL NUMBER</u>	<u>INVENTORS</u>	<u>ALLERGAN NO.</u>
10/104,899	Herbert K. Graham	16897-CIP
10/008,722	Aoki; et al.	16952-CON-DIV5-CIP
10/365,082	Aoki; et al.	16952-CON-DIV5-CIP- CON (BOT)
10/108,714	Regan; et al.	17023-DIV-CIP-CON
09/903,954	Michael E. Garst	17095-FWC-CIP-CON
09/998,358	Teng; et al.	17170-DIV2
10/017,660	Joseph S. Adorante	17219-CIP-CON3
10/116,492	Joseph S. Adorante	17219-CIP-CON4
09/367,712	John Sefton	17224
09/264,531	John Sefton	17235
not assigned	Olejnuk; et al	17237-CON2-CIP-CON3
09/329,752	Chow; et al.	17243-CIP2
09/815,362	Chow; et al.	17243-CIP3
09/108,298	Nagpal; et al.	17253
09/294,980	Dolly; et al.	17259
	(only the portion assigned by Roger Aoki)	
09/989,295	Beck; et al.	17273-CON
09/760,133	Firestone; et al.	17278-CON
09/288,326	Sachs; et al.	17282
09/548,409	Sachs; et al.	17282-CIP
10/304,665	Klein; et al.	17276-CIP-CON
09/919,195	Massaro; et al.	17293-DIV
	(only the portion assigned by Chandraratna)	
10/305,049	Massaro; et al.	17294-CON
	(only the portion assigned by Chandraratna)	
09/548,896	Chandraratna; et al.	17295
	(only the portion assigned by Chandraratna)	
09/624,129	Muller; et al.	17300-CIP
09/838,772	Cheetham; et al.	17300-CIP2
10/236,712	Muller; et al.	17300-CIP-CON
10/194,834	Muller; et al.	17301-DIV2
09/590,447	Forman; et al.	17302
	(only that portion assigned by Beard and Chandraratna)	
09/621,179	Chandraratna; et al.	17304
09/371,354	Stephen Donovan	17310
10/114,740	Gregory F. Brooks	17310-CIP
09/648,692	Dolly; et al.	17311
09/500,147	Terrence J. Hunt	17319
10/047,058	Terrence J. Hunt	17319-CIP
10/360,098	Terrence J. Hunt	17319-CIP-CIP


APPENDIX "A" (Page 2)

<u>SERIAL NUMBER</u>	<u>INVENTORS</u>	<u>ALLERGAN NO.</u>
10/135,595	Vasudevan; et al.	17321
10/038,215	Evan B. Dreyer	17322-CON
09/692,811	Stephen Donovan	17324
09/810,601	Stephen Donovan	17324-CIP
10/071,826	Donovan; et al.	17326-CIP2
09/552,823	Pacifici; et al.	17327-CIP
10/199,222	Aoki; et al.	17328-CON
09/489,667	Stephen Donovan	17329
09/938,112	Stephen Donovan	17329-DIV
09/625,098	Stephen Donovan	17329-CIP
10/039,520	Beard; et al.	17331-REF
09/533,680	Beard; et al.	17331
09/706,211	Stephen Donovan	17341-DIV
09/706,173	Stephen Donovan	17341-DIV2
09/706,172	Stephen Donovan	17341-DIV3
09/706,215	Stephen Donovan	17341-DIV5
10/017,834	Voet; et al.	17341-CIP2
10/099,238	Voet; et al.	17341-CIP3
09/704,464	Stephen Donovan	17342-DIV2
09/835,949	Stephen Donovan	17342-CON
09/971,869	Stephen Donovan	17342-DIV-CON
09/815,156	Klein; et al.	17346
09/850,835	Kusari; et al.	17347
09/548,315	Chow; et al.	17351
09/778,975	Chow; et al.	17351-CIP
09/561,106	Stephen Donovan	17354
09/904,018	Olejniak; et al.	17361
10/236,566	Olejniak; et al.	17361-CON
10/299,386	Olejniak; et al.	17361-DIV
10/146,224	Old; et al.	17366
10/300,492	Burk; et al.	17373-CON-CIP-CON
10/004,230	Steward; et al.	17376
09/640,852	Nehme; et al.	17377
09/651,235	Vasudevan; et al.	17379
10/079,993	Vasudevan; et al.	17382-DIV
10/364,225	Vasudevan; et al.	17382-DIV2
10/097,368	Vasudevan; et al.	17383-DIV
10/097,315	Vasudevan; et al.	17383-DIV2
10/212,533	Vasudevan; et al.	17386-DIV3
10/104,433	Burk; et al.	17390-CIP
09/847,935	Woodward; et al.	17392
10/155,925	Brooks; et al.	17396-CON
09/751,053	Gil; et al.	17399

APPENDIX "A" (Page 3)

<u>SERIAL NUMBER</u>	<u>INVENTORS</u>	<u>ALLERGAN NO.</u>
10/020,541	Wheeler; et al.	17400
09/998,718	Burke; et al.	17400-CIP
09/726,949	Lin; et al.	17408
10/051,952	Patricia S. Walker	17409-CIP
10/081,126	Gerald W. DeVries	17413
09/848,249	Woodward; et al.	17415
09/848,159	Yuan; et al.	17416
10/131,848	Huth; et al.	17421
09/814,604	Klein; et al.	17425
09/922,226	Zhao; et al.	17432
10/121,076	Robert T. Lyons	17433
09/882,720	Burk; et al.	17437
10/103,301	Burk; et al.	17437-CIP
10/346,828	Burk; et al.	17437-CON
10/294,521	Burk; et al.	17438-DIV
09/956,470	Liang; et al.	17440-CIP
09/918,847	Joshi; et al.	17442
09/904,753	Robert T. Lyons	17445
09/893,159	Woodward; et al.	17446
09/942,098	Steward; et al.	17451
09/942,024	Steward; et al.	17452
10/104,385	Forman; et al.	17453-CIP
09/954,610	Martin A. Voet	17455
10/143,076	Lam; et al.	17456
10/017,817	Chang; et al.	17462
10/016,850	Hughes; et al.	17468
10/016,036	David; et al.	17476
	(only that portion assigned by Robert David)	
10/100,638	Vasudevan; et al.	17485
10/082,691	Stephen Donovan	17486
10/133,094	Stanley W. Huth	17487
10/099,239	Martin A. Voet	17489
10/099,602	Lisa D. Hanin	17493
10/143,078	Stephen Donovan	17500

Morgan
Agreement



SECRETARY OF STATE

I, **BILL JONES**, Secretary of State of the State of California,
hereby certify:

That the attached transcript of 6 page(s) has
been compared with the record on file in this office, of
which it purports to be a copy, and that it is full, true
and correct.

IN WITNESS WHEREOF, I execute this
certificate and affix the Great Seal of
the State of California this day of

JUN 18 2002

Bill Jones

Secretary of State

00678567

ENDORSED - FILED
in the office of the Secretary of State
of the State of California

AGREEMENT AND PLAN OF MERGER

JUN - 3 2002

BETWEEN

BILL JONES, Secretary of State

ALLERGAN SALES, INC.
(a California corporation)

AND

ALLERGAN SALES, LLC
(a Delaware limited liability company)

THIS AGREEMENT AND PLAN OF MERGER is made as of June 3, 2002 (this "Agreement of Merger"), by and between Allergan Sales, Inc., a California corporation (the "Corporation"), and Allergan Sales, LLC, a Delaware limited liability company (the "LLC", and collectively with the Corporation the "Constituent Companies").

WHEREAS, the Corporation was incorporated by the filing of Articles of Incorporation with the Secretary of State of the State of California on March 20, 1980; and

WHEREAS, the LLC was formed by the filing of a Certificate of Formation with the Secretary of State of the State of Delaware on February 25, 2002, and Allergan, Inc., a Delaware corporation and the sole member of the LLC (the "Member"), has entered into a Limited Liability Company Agreement dated as of February 25, 2002 (the "Operating Agreement");

NOW, THEREFORE, the parties hereby agree as follows:

1. Upon the terms and subject to the conditions hereof and in accordance with the California General Corporation Law (the "CGCL") and the Delaware Limited Liability Company Act (the "DLLCA"), the Corporation shall be merged with and into the LLC (the "Merger") at the Effective Time (as hereinafter defined). Following the Merger, the separate existence of the Corporation shall cease, and the LLC shall continue as the surviving entity (the "Surviving Entity") and shall succeed to and assume all of the rights and obligations of the Corporation in accordance with the CGCL and the DLLCA.

2. The parties hereto shall cause the Merger to be consummated by filing this Agreement of Merger, along with a Certificate of Merger, with the Secretary of State of the State of California pursuant to Section 1113 of the CGCL, and by filing a Certificate of Merger (the "Certificate of Merger") with respect thereto with the Secretary of State of the State of Delaware pursuant to Section 18-209 of the DLLCA. When used in this Agreement of Merger, the term "Effective Date" shall mean the date of filing of the Certificate of Merger with the Secretary of State of the State of Delaware.

3. The Merger shall have the effects set forth in Section 1113(i) of the CGCL and Section 18-209(g) of the DLLCA. Without limiting the generality of the foregoing, and subject thereto, at the Effective Time, except as otherwise provided herein, all of the property,

rights, privileges, powers and franchises of the Corporation and the LLC shall rest in the Surviving Entity, and all debts, liabilities and duties of the Corporation and the LLC shall become the debts, liabilities and duties of the Surviving Entity.

4. As of the Effective Time, by virtue of the Merger and without any action on the part of the Member of the LLC, or the shareholders or the Board of Directors of the Corporation, each share of capital stock in the Corporation issued and outstanding immediately prior to the Effective Time shall be canceled and extinguished without consideration. The membership interests of the LLC outstanding immediately prior to the Effective Time shall continue to be outstanding and shall not be affected by the Merger.

5. If, at any time after the Effective Time, the Surviving Entity shall consider or be advised that any deeds, bills of sale, assignments or assurances or any other acts or things are necessary, desirable or proper (a) to vest, perfect or confirm, of record or otherwise, in the Surviving Entity, its right, title or interest in, to or under any of the rights, privileges, powers, franchises, properties or assets of either of the Constituent Companies, or (b) otherwise to carry out the purposes of this Agreement of Merger, the Surviving Entity and its proper authorized representatives shall be authorized to execute and deliver, in the name and on behalf of either of the Constituent Companies, all such deeds, bills of sale, assignments and assurances and do, in the name and on behalf of each of the Constituent Companies, all such other acts and things necessary, desirable or proper to vest, perfect or confirm its right, title or interest in, to or under any of the rights, privileges, powers, franchises, properties or assets of such constituent Company and otherwise to carry out the purposes of this Agreement of Merger.

6. As required by the CGCL, the Surviving Entity hereby agrees to (i) be served in the State of California in any proceeding for the enforcement of an obligation of any Constituent Company and in any proceeding to enforce the rights of any holder of a dissenting interest or dissenting shares in a constituent domestic limited liability company or domestic other business entity; (ii) irrevocably appoint the Secretary of State of the State of California as its agent for service of process, which process may be forwarded to 2525 Dupont Drive, Irvine, California 92612; and (iii) promptly pay the holder of any dissenting interest or dissenting share in a constituent domestic limited liability company or domestic other business entity the amount to which that person is entitled under California law.

IN WITNESS WHEREOF, the undersigned have caused this Agreement of Merger to be executed by their respective officers or representatives thereunto duly authorized as of the date first above written.

ALLERGAN SALES, INC.,
a California corporation

By: 

Jeffrey L. Edwards
Vice President

By: 

Matthew J. Maletta
Assistant Secretary

ALLERGAN SALES, LLC,
a Delaware limited liability company

By: ALLERGAN, INC., its Sole Member

By: 

Name: Matthew J. Maletta

Title: Assistant Secretary

**CERTIFICATE OF APPROVAL
OF
AGREEMENT AND PLAN OF MERGER**

Jeffrey L. Edwards and Matthew J. Maletta state and certify that:

1. They are the Vice President and Assistant Secretary, respectively, of Allergan Sales, Inc., a California corporation.

2. The Agreement and Plan of Merger in the form attached was duly approved by the Board of Directors and the sole stockholder of the corporation.

3. There is only one class of shares and the total number of outstanding shares is 1,000 shares of Common Stock.


4. Approval of the Agreement and Plan of Merger by the holder of 100% of the outstanding shares of Common Stock was the vote required to approve the Agreement and Plan of Merger. The percentage of the outstanding shares of the corporation's shares entitled to vote on the Agreement of Merger which voted to approve the Agreement of Merger equaled the vote required.

5. No vote of the stockholders of the corporation's parent, Allergan, Inc., was required to approve the Agreement and Plan of Merger.

We further declare under penalty of perjury under the laws of the State of California that the matters set forth in this certificate are true and correct of our own knowledge.

Date: June 3, 2002


Jeffrey L. Edwards
Vice President


Matthew J. Maletta
Assistant Secretary



State of California
Bill Jones
Secretary of State

OTHER BUSINESS ENTITY
CERTIFICATE OF MERGER

(Corporations Code Sections 1113(g)(1) and (2), 6018.1, 6018.1 and 12540.1)

Filing Fee - Please see instructions.

IMPORTANT - Read instructions before completing this form.

This Space For Filing Use Only

1. Name of surviving entity: Allergan Sales, LLC	2. Type of entity: LLC	3. Secretary of State File Number: 200216110097	4. Jurisdiction: Delaware
5. Name of disappearing entity: Allergan Sales, Inc.	6. Type of entity: Corporation	7. Secretary of State File Number: C0978306	8. Jurisdiction: California
9. Future effective date, if any:		Day	Year

Surviving Entity		Disappearing Entity	
Each class entitled to vote	Percentage of vote required	Each class entitled to vote	Percentage of vote required
Sole Member	100%	Sole Shareholder	100%
		1,000 common shares issued	

10. If a vote was required enter the outstanding interests of each class entitled to vote on the merger and the percentage of vote required:
equalled or exceeded the vote required.

11. The principal terms of the agreement of merger were approved by a vote of the number of interests or shares of each class that
[] No vote of the shareholders of the parent party was required. [] The required vote of the shareholders of the parent party was obtained.

SECTION 13 IS ONLY APPLICABLE IF THE SURVIVING ENTITY IS A DOMESTIC LIMITED LIABILITY COMPANY, DOMESTIC LIMITED PARTNERSHIP OR PARTNERSHIP.

13. Requisite changes to the information set forth in the Articles of Organization, Certificate of Limited Partnership or Statement of Partnership Authority of the surviving limited liability company, limited partnership or partnership resulting from the merger. Attach additional pages, if necessary.

SECTION 14 IS APPLICABLE IF THE SURVIVING ENTITY IS AN OTHER BUSINESS ENTITY.

14. Principal business address of the surviving other business entity:

Address: **2525 Dupont Drive**
City: **Irvine**

State: **California**

Zip: **92612**

15. Other information required to be stated in the Certificate of Merger by the laws under which each constituent other business entity is organized. Attach additional pages if necessary.

16. Statutory or other basis under which each foreign other business entity is authorized to effect the merger:
Delaware Limited Liability Company Act Section 18-209

17. Number of pages attached, if any: **1**

18. I certify that the statements contained in this document are true and correct of my own knowledge. I declare that I am the person who is executing this instrument, which execution is my act and deed.

See Attached
Signature of Authorized Person for the Surviving Entity Date

Type or Print Name and Title of Person Signing Date

See Attached
Signature of Authorized Person for the Surviving Entity Date

Type or Print Name and Title of Person Signing Date

See Attached
Signature of Authorized Person for the Disappearing Entity Date

Type or Print Name and Title of Person Signing Date

See Attached
Signature of Authorized Person for the Disappearing Entity Date

Type or Print Name and Title of Person Signing Date

For an entity that is a business trust, real estate investment trust or an unincorporated association, set forth the provision of law or other basis for the authority of the person signing.

FORM OBE Merger-1 - Approved by Secretary of State

ATTACHMENT PAGE
TO
OTHER BUSINESS ENTITY
CERTIFICATE OF MERGER

18. Signature of Authorized person for the Surviving Entity

Dated: June 3, 2002

ALLERGAN SALES, LLC,
a Delaware limited liability company

ALLERGAN, INC.,
a Delaware corporation,
its sole member

By: Matthew J. Maletta

Name: Matthew J. Maletta

Title: Assistant Secretary

Signature of Authorized person for the Disappearing Entity

Dated: June 3, 2002

ALLERGAN SALES, INC.,
a California corporation

By: Jeffrey L. Edwards

Name: Jeffrey L. Edwards

Title: Vice President

By: Matthew J. Maletta

Name: Matthew J. Maletta

Title: Assistant Secretary




Delaware

PAGE 1

The First State

I, HARRIET SMITH WINDSOR, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF MERGER, WHICH MERGES:

"ALLERGAN SALES, INC.", A CALIFORNIA CORPORATION,
WITH AND INTO "ALLERGAN SALES, LLC" UNDER THE NAME OF
"ALLERGAN SALES, LLC", A LIMITED LIABILITY COMPANY ORGANIZED AND
EXISTING UNDER THE LAWS OF THE STATE OF DELAWARE, AS RECEIVED
AND FILED IN THIS OFFICE THE THIRD DAY OF JUNE, A.D. 2002, AT 9
O'CLOCK A.M.



Harriet Smith Windsor
Harriet Smith Windsor, Secretary of State

3496059 8100M

AUTHENTICATION: 1809761

DATE: 06-03-02

**CERTIFICATE OF MERGER
OF
ALLERGAN SALES, INC.
(a California corporation)
WITH AND INTO
ALLERGAN SALES, LLC
(a Delaware limited liability company)**

(Pursuant to Section 18-209 of the
Delaware Limited Liability Company Act)

Pursuant to the provisions of Section 18-209 of the Delaware Limited Liability Company Act ("DLLCA"), the undersigned surviving limited liability company submits the following Certificate of Merger for filing and certifies that:

FIRST: The name and jurisdiction of formation or incorporation of the limited liability company and corporation which are parties to the merger (the "constituent entities") are as follows:

<u>Name of Entity</u>	<u>State of Formation or Incorporation</u>
Allergan Sales, Inc.	California
Allergan Sales, LLC	Delaware

SECOND: An Agreement and Plan of Merger (the "Merger Agreement") between the constituent entities has been approved and executed by each of the constituent entities which are to merge in accordance with the requirements of Section 18-209 of the DLLCA.

THIRD: The name of the surviving limited liability company is: Allergan Sales, LLC (the "Surviving Entity").

FOURTH: The merger shall become effective upon filing of this Certificate of Merger.

FIFTH: The executed Merger Agreement is on file at the office of the Surviving Entity, the address of which is 2525 Dupont Drive, Irvine, California 92612.

SIXTH: A copy of the Merger Agreement will be furnished by the Surviving Entity, on request and without cost, to any member of the Surviving Entity or to any person holding an interest in the entity which is to merge with and into the Surviving Entity.

STATE OF DELAWARE
SECRETARY OF STATE
DIVISION OF CORPORATIONS
FILED 09:00 AM 06/03/2002
020354968 - 3496059

IN WITNESS WHEREOF, this Certificate of Merger has been duly executed as of the 3rd day of June, 2002, and is being filed in accordance with Section 18-209 of the DLLCA by a duly authorized person on behalf of Allergan Sales, LLC.

ALLERGAN SALES, LLC,
a Delaware limited liability company

ALLERGAN, INC.,
a Delaware corporation,
its sole member

By: 

Name: Matthew J. Maletta

Title: Assistant Secretary